What Syapse does

Syapse is a healthcare technology company that built and operates a Learning Health Network aggregating de-identified real-world clinical data from community oncology providers to generate evidence for precision medicine, drug development, and clinical decision support. The company appears to have evolved its commercial identity toward the N-Power Medicine brand, whose platform centers on three core products: the Kaleido Registry (a consented prospective data collection program with 12,000+ enrolled patients and a 95% consent rate), N-Power Prospective External Controls (purpose-built comparator cohorts mirroring targeted trial protocols for phase II-III decision making), and the N-Power Community Trial Accelerator (a research-ready network enabling systematic pre-screening and signal-based site activation). The underlying technology combines an AI-enabled human-in-the-loop platform with a point-of-care solution that integrates with any EHR without disrupting physician workflow, holding HIPAA, HITRUST CSF, ISO 27001, and ISO 9001 certifications.

Syapse monetizes this platform through enterprise B2B contracts with two primary customer segments: biopharmaceutical companies, which purchase real-world evidence and prospective external control cohorts to de-risk oncology drug development, and community oncology providers, which gain access to clinical decision support, research participation, and operational savings (reported at 5-10 hours per physician per week). Pricing is quote-based and not publicly disclosed, but the recurring, contract-based nature of biopharma engagements and the network-participation model with providers point to a subscription- and services-oriented revenue mix. The company was founded in 2008, is headquartered in San Francisco, operates with 51-100 employees, and has raised approximately $222.6 million in cumulative venture and growth funding across nine disclosed rounds since 2011, most recently a $35 million growth investment led by Innovatus Capital Partners in July 2022.

Name

Syapse

Legal name

Syapse

Website

https://syapse.com/

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

51–100 employees

Short description

Syapse (operating commercially as N-Power Medicine) operates an oncology Learning Health Network and clinical research platform, selling real-world evidence, prospective external controls, and trial acceleration services to biopharmaceutical companies and community oncology providers.

Ownership category

akta.pro rank

Product category

Real-World Evidence Platform

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Misc Health & Allied Services, Nec (8090), Services-Computer Processing & Data Preparation (7374)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

Keywords

• Real-world evidence
• Precision medicine analytics
• Oncology data platform
• Clinical research network
• Healthcare data analytics

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Real-World Evidence Analytics Services: Syapse generates revenue by providing real-world evidence services to biopharmaceutical companies and healthcare providers through its Learning Health Network. The company aggregates clinical data from provider networks and offers analytics services to support precision medicine initiatives, drug development, and clinical decision-making.

Go-to-market motion1 record

Distribution channels1 record

Core offering

Syapse operates a Learning Health Network that aggregates real-world clinical, molecular, and outcomes data from community oncology providers to generate real-world evidence (RWE). The company sells data-driven products and platform capabilities to biopharmaceutical companies for clinical development and to healthcare providers for point-of-care decision support in precision oncology.

Product overview

N-Power Medicine offers a clinical research platform built on a novel single workflow that makes routine care and research one and the same. The core product portfolio includes the Kaleido Registry (a prospective data collection program with 12,000+ patients enrolled), N-Power Prospective External Controls (purpose-built comparator cohorts for phase II-III decision making), and N-Power Community Trial Accelerator (a research-ready network enabling rapid trial enrollment). These are powered by a Human-in-the-Loop Platform combining AI automation with expert human oversight, and a Point-of-Care Technology Solution that integrates with existing EHR systems.

Differentiator

Problem solved

Functional benefit

Products and services

• Kaleido Registry

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• Healthcare ProviderscoreStrategic or Co-development PartnerSyapse partners with healthcare providers (hospitals, cancer centers, oncology practices) through its Learning Health Network. Providers contribute de-identified clinical data and in return gain access to real-world evidence analytics and the ability to participate in clinical research initiatives.
• Biopharmaceutical CompaniescoreStrategic or Co-development PartnerSyapse serves biopharmaceutical companies by providing real-world evidence generated from its Learning Health Network. These partnerships support precision medicine initiatives, clinical trial design, and post-market surveillance for pharmaceutical therapies.

Scale indicators3 records

Direct peers

• Flatiron Health: An oncology-specific real-world evidence and EHR company acquired by Roche for $1.9B. It is the most direct competitor to Syapse, offering oncology data analytics, clinical trial support, and RWE services to biopharma, with a similarly large provider network.
• Tempus: A precision medicine company combining genomic sequencing, AI-driven analytics, and a large oncology data library to support drug development and clinical care. Tempus competes directly with Syapse in providing RWE and molecular data to biopharma clients and providers.
• ConcertAI: An oncology real-world evidence and AI company serving both biopharma and providers with synthetic control arms, trial design, and provider data networks. It is a head-to-head competitor in the oncology RWE market Syapse serves.
• COTA Healthcare: An oncology-focused real-world data and analytics company that partners with providers and biopharma to generate RWE for clinical and commercial decisions. COTA competes in the same oncology RWE and clinical trial support market as Syapse.

Broad incumbents

• Foundation Medicine: A molecular profiling and genomic data company (owned by Roche) that combines comprehensive genomic testing with a large clinico-genomic database. While broader in scope, it competes with Syapse in oncology RWE and precision medicine data for biopharma.
• Medidata Solutions: A leading clinical trial technology platform (part of Dassault Systèmes) offering electronic data capture, trial design, and increasingly RWE capabilities. Medidata competes with Syapse in the clinical trial enablement and data analytics space for biopharma sponsors.
• IQVIA: A global CRO and healthcare data powerhouse that operates at scale across clinical trial operations, RWE, and commercial analytics. IQVIA is a broad incumbent with overlapping capabilities to Syapse's clinical research support and real-world evidence services.
• Oracle Health (Cerner): A major EHR and healthcare data platform that provides population-level clinical data infrastructure, including research and analytics capabilities. As a broad incumbent with deep hospital and oncology clinic penetration, Oracle Health represents both a potential partner and competitive threat to Syapse's provider data network strategy.

Emerging players

• Deep 6 AI: An AI-powered clinical trial matching and patient recruitment platform that mines EHR data to surface eligible patients. Deep 6 overlaps with Syapse's Community Trial Accelerator in helping biopharma sponsors identify and enroll patients in oncology trials.
• nference: An AI-driven biomedical data analytics company that synthesizes real-world clinical, molecular, and biomedical literature data for biopharma R&D. nference overlaps with Syapse in providing AI-enabled real-world evidence for drug development, particularly in oncology.

Market position

Strengths5 records

Weaknesses5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/Syapse
• Facebookfacebook.com/118481934909472

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds9 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syapse